Chris Schott
Stock Analyst at JP Morgan
(3.58)
# 846
Out of 4,996 analysts
138
Total ratings
58.51%
Success rate
3.37%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $135 → $145 | $112.10 | +29.35% | 7 | Sep 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,100 → $1,050 | $724.54 | +44.92% | 22 | Sep 16, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $9.75 | +43.59% | 3 | Sep 16, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $235 | $220.61 | +6.52% | 3 | Sep 16, 2025 | |
| PRGO Perrigo Company | Maintains: Overweight | $38 → $35 | $21.45 | +63.17% | 12 | Aug 7, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $550 → $675 | $632.22 | +6.77% | 8 | Aug 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $563.90 | +41.87% | 8 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $18.34 | +25.41% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $137.37 | +27.39% | 4 | May 5, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $143.50 | +60.28% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $20 | $10.21 | +95.89% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $35.04 | +19.86% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $272.98 | -1.09% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $23.76 | +43.10% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $78.56 | +59.11% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $9.52 | +47.06% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.50 | +633.33% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $19.61 | +1.99% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.48 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $44.12 | +76.79% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $19.05 | +4,886.88% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.07 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.24 | +98.10% | 3 | Nov 2, 2018 |
Gilead Sciences
Sep 16, 2025
Maintains: Overweight
Price Target: $135 → $145
Current: $112.10
Upside: +29.35%
Eli Lilly and Company
Sep 16, 2025
Maintains: Overweight
Price Target: $1,100 → $1,050
Current: $724.54
Upside: +44.92%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $9.75
Upside: +43.59%
AbbVie
Sep 16, 2025
Maintains: Overweight
Price Target: $200 → $235
Current: $220.61
Upside: +6.52%
Perrigo Company
Aug 7, 2025
Maintains: Overweight
Price Target: $38 → $35
Current: $21.45
Upside: +63.17%
IDEXX Laboratories
Aug 4, 2025
Maintains: Overweight
Price Target: $550 → $675
Current: $632.22
Upside: +6.77%
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $563.90
Upside: +41.87%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $18.34
Upside: +25.41%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $137.37
Upside: +27.39%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $143.50
Upside: +60.28%
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $10.21
Upside: +95.89%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $35.04
Upside: +19.86%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $272.98
Upside: -1.09%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $23.76
Upside: +43.10%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $78.56
Upside: +59.11%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $9.52
Upside: +47.06%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.50
Upside: +633.33%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $19.61
Upside: +1.99%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.48
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $44.12
Upside: +76.79%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $19.05
Upside: +4,886.88%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.24
Upside: +98.10%